# EXHIBIT
# AI

[redacted]

**APPENDIX L-3—U.S. PATENT NO. 12,048,692 INFRINGEMENT CONTENTIONS**

[redacted]



**4. Element 1[d]: "wherein the patient has a low peak inspiratory flow rate."**

As discussed above, at least some HCPs will select COPD patients for treatment with Mankind's ANDA product based on the patient having an $FEV_1$ of less than about 50%, and, as discussed below, at least a subset of those patients will have a low peak inspiratory flow rate (PIFR). The phrase "low peak inspiratory flow rate" is defined in the specification as "a peak inspiratory flow rate less than about 60 L/min." ('692 patent at 4:22-23).